|
SEER
|
BRCA2 carriers
|
Unadjusted OR (95 % CI)
|
Adjusted ORa (95 % CI)
|
---|
|
Number
|
Percent
|
Number
|
Percent
| | |
---|
Totalb
|
6351
| |
326
| | | |
Morphology
|
Ductal carcinoma
|
5265
|
86.2
|
253
|
95.1
|
Reference
|
Reference
|
Lobular carcinoma
|
82
|
1.5
|
4
|
1.5
|
1.02 (0.37–2.79)
|
1.00 (0.36–2.74)
|
Medullary Carcinoma
|
16
|
0.3
|
2
|
0.8
|
2.60 (0.59–11.38)
|
2.34 (0.52–10.39)
|
TNM stage
|
0–1
|
1699
|
34.9
|
44
|
29.5
|
Reference
|
Reference
|
2
|
1990
|
40.9
|
70
|
47.0
|
1.36 (0.93.–1.99)
|
1.37 (0.93–2.01)
|
3–4
|
1181
|
24.2
|
35
|
23.5
|
1.14 (0.73–1.77)
|
1.11 (0.72–1.73)
|
Histologic grade
|
Grade 1
|
632
|
12.9
|
8
|
3.5
|
Reference
|
Reference
|
Grade 2
|
2432
|
49.7
|
92
|
39.8
|
2.99 (1.44–6.19)
|
2.98 (1.44–6.19)
|
Grade 3
|
1834
|
37.4
|
131
|
56.7
|
5.64 (2.75–11.60)
|
5.53 (2.69–11.39)
|
Lymph node status
|
Negative
|
2773
|
58.0
|
123
|
50.2
|
Reference
|
Reference
|
Positive
|
2009
|
42.0
|
122
|
49.8
|
1.37 (1.05–1.78)
|
1.28 (0.98–1.67)
|
ER status
|
Negative
|
229
|
5.3
|
8
|
3.3
|
Reference
|
Reference
|
Positive
|
4064
|
94.7
|
236
|
96.7
|
1.66 (0.81–3.41)
|
1.95 (0.93–4.06)
|
PR status
|
Negative
|
627
|
15.0
|
30
|
13.2
|
Reference
|
Reference
|
Positive
|
3562
|
85.0
|
198
|
86.8
|
1.16 (0.79–1.72)
|
1.30 (0.88–1.92)
|
HER2 status
|
Negative
|
627
|
87.8
|
126
|
83.4
|
Reference
|
Reference
|
Positive
|
87
|
12.2
|
25
|
16.6
|
1.43 (0.88–2.32)
|
1.30 (0.79–2.13)
|
Subtypes
|
ER+ and/or PR+, HER2−
|
608
|
87.5
|
118
|
81.9
|
Reference
|
Reference
|
ER+ and/or PR+, HER2+
|
80
|
11.5
|
22
|
15.3
|
1.42 (0.85–2.36)
|
1.28 (0.76–2.17)
|
ER−, PR−, HER2+
|
7
|
1.0
|
2
|
1.4
|
1.47 (0.30–7.18)
|
1.09 (0.22–5.45)
|
Triple-negative (ER−, PR−, HER2−)
|
0
|
0.0
|
2
|
1.4
|
–
|
–
|
ER+ and/or PR+, HER2− vs. others
| | | | |
1.54 (0.95–2.49)
|
1.38 (0.84–2.27)
|
-
BRCA2 breast cancer 2, early onset gene, CI confidence interval, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, OR odds ratio, PR progesterone receptor, TNM tumour, node, metastasis
- Significant results are indicated by boldface type
-
aAnalyses adjusted for age at diagnosis and calendar year of diagnosis
-
bSome data for each pathologic feature are not available